[1]
Bijak M, Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules (Basel, Switzerland). 2017 Nov 10;
[PubMed PMID: 29125572]
[3]
Bedogni G,Miglioli L,Masutti F,Tiribelli C,Marchesini G,Bellentani S, Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (Baltimore, Md.). 2005 Jul;
[PubMed PMID: 15895401]
[4]
Velussi M,Cernigoi AM,De Monte A,Dapas F,Caffau C,Zilli M, Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of hepatology. 1997 Apr;
[PubMed PMID: 9126802]
[5]
Hajiaghamohammadi AA,Ziaee A,Oveisi S,Masroor H, Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepatitis monthly. 2012 Aug;
[PubMed PMID: 23087748]
Level 3 (low-level) evidence
[6]
Kazazis CE,Evangelopoulos AA,Kollas A,Vallianou NG, The therapeutic potential of milk thistle in diabetes. The review of diabetic studies : RDS. 2014 Summer;
[PubMed PMID: 25396404]
[7]
Huseini HF,Larijani B,Heshmat R,Fakhrzadeh H,Radjabipour B,Toliat T,Raza M, The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytotherapy research : PTR. 2006 Dec;
[PubMed PMID: 17072885]
Level 1 (high-level) evidence
[8]
Loguercio C,Federico A,Trappoliere M,Tuccillo C,de Sio I,Di Leva A,Niosi M,D'Auria MV,Capasso R,Del Vecchio Blanco C, The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Digestive diseases and sciences. 2007 Sep;
[PubMed PMID: 17410454]
Level 3 (low-level) evidence
[9]
Loguercio C,Festi D, Silybin and the liver: from basic research to clinical practice. World journal of gastroenterology. 2011 May 14;
[PubMed PMID: 21633595]
[10]
Abenavoli L,Bellentani S, Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert review of gastroenterology
[PubMed PMID: 24134155]
[11]
Schümann J,Prockl J,Kiemer AK,Vollmar AM,Bang R,Tiegs G, Silibinin protects mice from T cell-dependent liver injury. Journal of hepatology. 2003 Sep;
[PubMed PMID: 12927918]
[12]
Trouillas P,Marsal P,Svobodová A,Vostálová J,Gazák R,Hrbác J,Sedmera P,Kren V,Lazzaroni R,Duroux JL,Walterová D, Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. The journal of physical chemistry. A. 2008 Feb 7;
[PubMed PMID: 18193843]
[13]
Wellington K,Jarvis B, Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2001;
[PubMed PMID: 11520257]
[14]
Cacciapuoti F,Scognamiglio A,Palumbo R,Forte R,Cacciapuoti F, Silymarin in non alcoholic fatty liver disease. World journal of hepatology. 2013 Mar 27;
[PubMed PMID: 23556042]
[15]
Borsari M,Gabbi C,Ghelfi F,Grandi R,Saladini M,Severi S,Borella F, Silybin, a new iron-chelating agent. Journal of inorganic biochemistry. 2001 Jun;
[PubMed PMID: 11410232]
[16]
Fabregat I,Moreno-Càceres J,Sánchez A,Dooley S,Dewidar B,Giannelli G,Ten Dijke P, TGF-β signalling and liver disease. The FEBS journal. 2016 Jun;
[PubMed PMID: 26807763]
[17]
Hruby K,Csomos G,Fuhrmann M,Thaler H, Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human toxicology. 1983 Apr;
[PubMed PMID: 6862461]
[18]
Kawaguchi-Suzuki M,Frye RF,Zhu HJ,Brinda BJ,Chavin KD,Bernstein HJ,Markowitz JS, The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug metabolism and disposition: the biological fate of chemicals. 2014 Oct;
[PubMed PMID: 25028567]
[19]
Tamayo C,Diamond S, Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integrative cancer therapies. 2007 Jun;
[PubMed PMID: 17548793]